InvestorsHub Logo
Post# of 26891
Next 10
Followers 437
Posts 42954
Boards Moderated 2
Alias Born 05/08/2006

Re: None

Friday, 10/19/2018 12:29:06 PM

Friday, October 19, 2018 12:29:06 PM

Post# of 26891
Compensated Awareness Post View Disclaimer
QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Focused on Innovative Nicotine Delivery to Provide Healthier Alternatives to Lighting Up

Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) is on a quest in the development of healthier nicotine ingestion methods to provide consumers alternatives to lighting up. A recent article discussing the company’s novel drug delivery platform reads, “In a press release from August 2018, Lexaria announced a second-generation study in 40 rats. The study resulted in Lexaria’s formulation being four-times faster at reaching its peak level in brain tissue than the non-enhanced control formulation. In a press release (http://ibn.fm/d7ur9), Chris Bunka, chief executive officer of Lexaria, stated, ‘DehydraTECH delivery technology continues to demonstrate its superior effectiveness in delivering nicotine without the need for combustion or the need for inhalation whatsoever. Crossing the blood brain barrier is a significant achievement all on its own and this data confirms the outcome of our earlier first-generation test.’”

To view the full article, visit http://ibn.fm/S2Uxr

About Lexaria Bioscience Corp.
Lexaria Bioscience Corp. licenses disruptive patented delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and has patents granted in the USA and in Australia for utilization of its DehydraTECH™ delivery technology. Lexaria’s technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. For more information, visit the company’s website at www.LexariaBioscience.com.

Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.